A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 1, Phase 2
- Study design
- NA · SINGLE GROUP · TREATMENT · NONE
- Evidence population
- Human clinical study registration
- Participants
- 72
- Population
- ALL · 40 Years to 64 Years
- Duration
- 2023-11-01 to 2026-10-30
- Intervention
- umbilical cord mesenchymal stem cell
- Comparator
- Not reported
- Outcomes measured
- Adverse effect — From the patients enrolled in the study until 30 days after the study ended.; Serve adverse effect — From the patients enrolled in the study until 30 days after the study ended.; the expression levels of pro-inflammatory cytokines — Before (day 0), after 90 days, and after 180 days of cell transpl…; the expression levels of anti-inflammatory cytokines — Before (day 0), after 90 days, and after 180 days of cell transp…; the inflammation balance — Before (day 0), after 90 days, and after 180 days of cell transplantation; Effect in diabetes patient — Before (day 0), after 90 days, and after 180 days of cell transplantation; Effect in dislipidemia patient — Before (day 0), after 90 days, and after 180 days of cell transplantation; Effect in obese patient — Before (day 0), after 90 days, and after 180 days of cell transplantation.
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Stem cells · 100%Title contains controlled term: stem cell. Abstract contains controlled term: stem cell. Source terminology contains: stem cell. Title supplies longevity context: aging. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.